A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

William Robinson Biography and Net Worth

Director of Atreca

Mr. William Robinson is the Director of Atreca.

What is William Hewitt Robinson's net worth?: The estimated net worth of William Hewitt Robinson is at least $28,409.00 as of March 15th, 2021. Mr. Robinson owns 368,948 shares of Atreca stock worth more than $28,409 as of April 20th. This net worth estimate does not reflect any other assets that Mr. Robinson may own. Learn More about William Hewitt Robinson's net worth.
How do I contact William Hewitt Robinson?: The corporate mailing address for Mr. Robinson and other Atreca executives is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. Atreca can also be reached via phone at (650) 595-2595 and via email at [email protected]. Learn More on William Hewitt Robinson's contact information.
Has William Hewitt Robinson been buying or selling shares of Atreca?: William Hewitt Robinson has not been actively trading shares of Atreca during the last quarter. Most recently, William Hewitt Robinson sold 5,000 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $16.89, for a transaction totalling $84,450.00. Following the completion of the sale, the director now directly owns 368,948 shares of the company's stock, valued at $6,231,531.72. Learn More on William Hewitt Robinson's trading history.
Who are Atreca's active insiders?: Atreca's insider roster includes Norman Greenberg (Insider), William Robinson (Director), and Tito Serafini (Insider). Learn More on Atreca's active insiders.
Are insiders buying or selling shares of Atreca?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 284,302 shares worth more than $118,980.45. The most recent insider tranaction occured on October, 19th when Major Shareholder Bros. Advisors Lp Baker sold 274,739 shares worth more than $109,895.60. Insiders at Atreca own 11.3% of the company. Learn More about insider trades at Atreca.
Information on this page was last updated on 10/19/2023.

William Hewitt Robinson Insider Trading History at Atreca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2021	Sell	5,000	$16.89	$84,450.00	368,948
2/16/2021	Sell	5,000	$19.07	$95,350.00	373,948
1/13/2021	Sell	2,741	$15.05	$41,252.05	381,207
12/14/2020	Sell	5,000	$16.67	$83,350.00	383,948
11/16/2020	Sell	5,000	$15.00	$75,000.00	388,948
10/13/2020	Sell	5,000	$15.71	$78,550.00	393,948
9/18/2020	Sell	5,000	$15.04	$75,200.00	398,948
8/14/2020	Sell	5,000	$15.00	$75,000.00	403,948
7/13/2020	Sell	5,000	$20.23	$101,150.00	412,542
6/22/2020	Sell	68	$20.05	$1,363.40	414,616
6/19/2020	Sell	10,245	$20.03	$205,207.35	414,616
6/15/2020	Sell	5,000	$18.55	$92,750.00	428,856
5/28/2020	Sell	600	$20.01	$12,006.00	429,861
5/26/2020	Sell	387	$20.00	$7,740.00	430,461
5/13/2020	Sell	5,000	$16.82	$84,100.00	434,748
4/16/2020	Sell	5,000	$16.25	$81,250.00	441,348

William Hewitt Robinson Buying and Selling Activity at Atreca

Atreca Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Today's Range

Now: $0.08

$0.08

$0.09

50 Day Range

MA: $0.17

$0.06

$0.32

2 Week Range

Now: $0.08

$0.05

$1.26

Volume

14,041 shs

Average Volume

266,538 shs

Market Capitalization

$3.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad